Lamivudine is an antiretroviral medicine used as part of combination therapy for HIV infection. It belongs to a group of medicines called nucleoside reverse transcriptase inhibitors, which work by interfering with an enzyme HIV needs to reproduce. Lamivudine is generally used together with other antiretroviral medicines.
Lamivudine is a nucleoside analogue that becomes active inside cells after undergoing phosphorylation. Its active form competes with naturally occurring nucleosides involved in viral DNA synthesis. When incorporated into the growing viral DNA chain, it prevents further extension, thereby interfering with HIV replication.
The medicine's role can be understood through several characteristics:
Lamivudine does not eliminate HIV from the body. Antiretroviral therapy instead aims to suppress viral replication and maintain control of the infection over the long term.
Combination antiretroviral therapy uses medicines with different mechanisms or resistance profiles to suppress HIV effectively. Lamivudine may be included in several treatment combinations, depending on factors such as previous treatment, resistance testing, kidney function, other medical conditions, and interactions with other medicines.
Important treatment considerations include:
Regular clinical monitoring helps healthcare professionals evaluate viral suppression, treatment response, tolerability, and other relevant health factors.
Lamivudine is also used in fixed-dose combination products containing other antiretroviral medicines. Combining medicines into a single formulation can simplify treatment for some patients, although the suitability of a particular formulation depends on the individual's clinical needs.
Like other medicines, lamivudine can cause adverse effects. Some people may experience symptoms such as headache, nausea, diarrhea, or fatigue. Serious reactions are less common but require medical attention. People should discuss persistent or concerning symptoms with their healthcare professional rather than stopping treatment independently.
Because lamivudine also has activity against hepatitis B, stopping a lamivudine-containing regimen in someone with HIV and hepatitis B can potentially lead to worsening hepatitis B. Treatment changes should therefore be managed by a healthcare professional.
Overall, lamivudine remains an important component of some antiretroviral treatment regimens. Its ability to inhibit HIV replication, compatibility with combination therapies, and availability in fixed-dose formulations contribute to its continuing role in HIV care. Appropriate regimen selection, adherence, monitoring, and consideration of resistance and coexisting infections are important parts of effective HIV treatment.